

Elsevier Editorial System(tm) for Biomaterials
Manuscript Draft

Manuscript Number: jbmt20639R1

Title: Combining Poly-Arginine with the Hydrophobic Counter-anion 4-(1-Pyrenyl)-Butyric Acid for Protein Transduction in Transdermal Delivery

Article Type: FLA Original Research

Section/Category: Biomaterials for the Delivery of Drugs, Genes, Vaccines and Active Biomolecules (BDGV)

Keywords: Transdermal delivery, Protein transduction, Poly-arginine, 11R, Tat, Hydroquinone, Melanin, Skin, Tyrosinase inhibitor

Corresponding Author: Dr. Hiroyuki Michiue, M.D. Ph.D

Corresponding Author's Institution: Okayama University

First Author: GERILE CANDAN, M.D.

Order of Authors: GERILE CANDAN, M.D.; Hiroyuki Michiue, M.D. Ph.D.; Sanae Ishikawa; Atsushi Fujimura, M.D.; Keiichiro Hayashi; Atsuhito Uneda, M.D.; Akiko Mori, Ph.D.; Iori Ohmori, M.D. Ph.D.; Tei-ichi Nishiki, Ph.D.; Hideki Matsui, M.D. Ph.D.; Kazuhito Tomizawa, M.D. Ph.D.

Abstract: Topical therapy is the most favored form of treatment for whitening against hyperpigmentation and sunburn because it lends itself to self-administration, patient compliance, and absence of systemic adverse effects. However, transdermal delivery of hydrophilic chemicals is difficult. The main purpose of this study is to develop a delivering system of hydrophilic drugs and proteins across the skin. Hydroquinone (HQ), a well-known tyrosinase inhibitor and antimelanogenesis compound, and enhanced green fluorescent protein (EGFP) were fused with eleven poly-arginine (11R). Both HQ-11R and EGFP-11R were efficiently delivered in B16 cells, a mouse melanoma cell line. HQ-11R was as effective as HQ alone at inhibiting melanin synthesis in B16 cells. EGFP-11R was efficiently delivered into cells of the epidermis with 4-(1-pyrenyl)-butyric acid (PB), a counteranion bearing an aromatic hydrophobic moiety, *in vivo*, but EGFP alone or EGFP-11R without PB was not. Finally, topical application of HQ-11R with PB significantly inhibited UV irradiation-induced pigmentation in guinea pigs compared with HQ alone. These results suggest that topical therapy using poly-arginine in combination with PB is useful for the delivery of hydrophilic drugs and proteins by the transdermal route.

1
2
3 **Abstract**
4
5

6 Topical therapy is the most favored form of treatment for whitening against
7 hyperpigmentation and sunburn because it lends itself to self-administration, patient
8 compliance, and absence of systemic adverse effects. However, transdermal delivery
9 of hydrophilic chemicals is difficult. The main purpose of this study is to develop a
10 delivering system of hydrophilic drugs and proteins across the skin. Hydroquinone
11 (HQ), a well-known tyrosinase inhibitor and antimelanogenesis compound, and
12 enhanced green fluorescent protein (EGFP) were fused with eleven poly-arginine (11R).
13 Both HQ-11R and EGFP-11R were efficiently delivered in B16 cells, a mouse
14 melanoma cell line. HQ-11R was as effective as HQ alone at inhibiting melanin
15 synthesis in B16 cells. EGFP-11R was efficiently delivered into cells of the epidermis
16 with 4-(1-pyrenyl)-butyric acid (PB), a counteranion bearing an aromatic hydrophobic
17 moiety, *in vivo*, but EGFP alone or EGFP-11R without PB was not. Finally, topical
18 application of HQ-11R with PB significantly inhibited UV irradiation-induced
19 pigmentation in guinea pigs compared with HQ alone. These results suggest that
20 topical therapy using poly-arginine in combination with PB is useful for the delivery of
21 hydrophilic drugs and proteins by the transdermal route.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. Introduction

Transdermal drug delivery has several advantages over other administration routes including convenience for the patient, avoidance of hepatic metabolism, and easy withdrawal of treatment if necessary [1]. Despite extensive studies of transdermal drug delivery, only a few drug formulations are commercially available [1,2]. Almost no hydrophilic chemicals and proteins can be delivered by transdermal systems. One reason for this is that the stratum corneum acts as a barrier to exogenous substances [1]. Another reason is that hydrophilic chemicals and proteins have no ability to penetrate cell membranes [3]. To develop transdermal drug delivery systems, these problems must be overcome using appropriate physical and chemical means. To enhance the ability of drug molecules to penetrate skin, several methods have been reported [4]. Occlusive dressing, a technique which hydrates the stratum corneum, is perhaps the simplest approach [4,5]. Chemical enhancers such as dimethylsulphoxide (DMSO), Azone, oleic acid, propylene glycol, terpenes and terpenoids that improve the diffusion coefficient of a substance in the stratum corneum by interacting with intercellular lipids have been studied [4,6]. As physical modifications, iontophoresis, which promotes skin permeability by using electropotential energy, electroporation, which produces small pores on the surface of the stratum corneum by adding electric pulses,

1
2
3 sonophoresis, which utilizes the cavitation of ultrasonic waves, and microneedles which
4
5
6 produce new permeation routes, have been studied [4,6]. However, both chemical and
7
8
9 physical enhancers to induce irritation, cause damage, and reduce the skin barrier
10
11
12 function [4]. Recent studies showed that liposome formulations are effective at
13
14
15 delivering chemicals and functional molecules through the stratum corneum. However,
16
17
18 they probably increase penetration only through the transappendageal route [6,7]. It is
19
20
21 desirable to deliver therapeutic agents to cells across the stratum corneum while main
22
23
24 taining the normal skin barrier function.
25
26

27
28 Protein transduction system is a widely accepted method of delivering proteins,
29
30
31 peptides, siRNA and biologically active compounds across the cell membrane by fusing
32
33
34 with cell-penetrating peptides (CPPs) such as poly-arginine and the protein transduction
35
36
37 domain of TAT [8-10]. This methodology attracted our attention not only as a means
38
39
40 of cell biological study but also because of its potential for pharmaceutical vectors [9].
41
42
43 CPP-fused proteins are rapidly internalized by lipid raft-dependent macropinocytosis
44
45
46 [11]. After internalization via the macropinocytotic pathway, the proteins are carried
47
48
49 to macropinosomes, where most of them are then degraded [11]. Recent studies have
50
51
52 shown that the ability to cross lipid bilayers and gain access to the cell interior of CPPs,
53
54
55 especially poly-arginine, is enhanced in the presence of the hydrophobic counter-anion
56
57
58
59
60
61
62
63
64
65

1
2
3 4-(1-pyrenyl)-butyric acid (pyrenebutyrate, PB) [12,13]. The negatively charged
4
5
6 counteranions and high hydrophobicity of PB can exert a great influence on the
7
8
9 translocation behavior of arginine peptides in artificial membranes [12,13]. These
10
11
12 features of the combination of poly-arginine and pyrenebutyrate are thought to be useful
13
14
15 for the transdermal delivery of hydrophilic chemicals.
16
17

18
19 Hydroquinone (HQ) is a tyrosinase inhibitor and a hydrophilic antimelanogenesis
20
21
22 compound used as an active ingredient in cosmetics and pharmaceuticals [14-16]. In
23
24
25 the present study, we investigated whether protein transduction using poly-arginine in
26
27
28 combination with PB was capable of delivering functional hydrophilic molecules and
29
30
31 proteins into skin.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 **2. Materials and methods**
4
5

6 *2.1. Cell Culture*
7
8

9
10 Mouse B16 melanoma cells (B16-4A5) were provided by the European Collection of
11
12 Cell Culture (ECACC). Cells were cultured in Dulbecco's modified Eagle's medium
13
14 (D-MEM, Life Technologies, Grand Island, NY) with 10% fetal calf serum (Life
15
16 Technologies), 100 U/ml penicillin, 100 U/ml streptomycin and 0.2 % L-glutamine
17
18 (Life Technologies). Cultures were maintained at 37 °C in 95% air and 5% CO₂ in a
19
20 humidified incubator.
21
22
23
24
25
26
27
28
29
30

31
32 *2.2. Peptide and HQ-11 synthesis*
33
34

35 1) Cys(Npys)-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg- Arg-Arg-Arg-NH₂
36
37

38 Peptide derivatives were assembled using an Applied Biosystems model 433 peptide
39
40 synthesizer with Rink Amide MBHA Resin (0.34 mmol/g, 0.25 mmol) as the starting
41
42 solid support. The protected peptide resin was treated with a deprotecting reagent
43
44 [TFA-TIS-H₂O (95/2.5/2.5/, v/v)] at room temperature for 2 h. The crude S-Npys
45
46 derivatives were isolated and purified by RP-HPLC. The purified Npys was used for
47
48 the final disulfide formation procedure.
49
50
51
52
53
54
55

56
57 2) Cys[(OH)₂C₆H₄S-]-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH₂·11TFA
58
59
60
61
62
63
64
65

1
2
3 HQ was conjugated with poly-arginine peptides as shown in Fig. 1. To an aqueous
4 solution (1.2 ml) of Cys(Npys)-11Arg-NH₂ (60 mg) was added
5
6 (OH)₂C₆H₄SH(2-mercaptohydroquinone, 3.6 mg, 0.8 eq) with stirring at room
7
8 temperature overnight under an Argon gas atmosphere. After the reaction was over,
9
10 the reaction mixture was directly subjected RP-HPLC [YMC ODS column (30 x 250
11
12 mm, 0.1%TFA/H₂O)]. The desired peptide was obtained as a TFA salt (25 mg), as
13
14 confirmed by RP-HPLC and Mass spectral analysis.
15

16 Cys[(OH)₂C₆H₄S-]-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH₂·11TFA;

17
18
19 Mol wt : 3232.6 as TFA salt, C₇₅H₁₄₄N₄₆O₁₄S₂ MW:1978.4, MS analysis : m/z
20
21 660.4(M 3H)₃, m/z 495.6([M 4H]₄), Purity : 94.5%.
22
23
24

25 26 27 28 29 30 31 32 33 34 35 36 37 38 *2.3. Protein/peptide transduction into cells* 39

40
41 The transduction of protein and peptide into cells was carried out as described
42 previously [12]. Briefly, cells were plated onto dishes (diameter 3 cm) and incubated
43
44 in D-MEM containing 10% FBS (Life Technologies), 1% penicillin and streptomycin
45
46 for 48 h in a humidified atmosphere containing 5% CO₂. After removal of the medium,
47
48 the cells were washed twice with PBS and incubated with 50 μM 4-(1-pyrenyl)-butyric
49
50 acid (PB, Sigma-Aldrich, St. Louis, MO) in PBS for 2 min at 37 °C. Cells were then
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 replaced with new PBS and protein or peptide dissolved in PBS was added. After 20
4
5
6 min, the cells were washed twice with PBS and incubated further in new medium for
7
8
9 the period indicated.
10

11 12 13 14 15 16 *2.4. Cell Viability Assay*

17
18
19 Cell viability was determined using a CellTiter-Glo® Luminescent Cell Viability
20
21
22 Assay kit (Promega, Madison, WI) following the manufacturer's instructions. After
23
24
25 the application of HQ and HQ-11R, B16 cells (1×10^3 per well) seeded onto 96-well
26
27
28 plates were cultured in D-MEM containing 10% fetal bovine serum, and 1 % penicillin
29
30
31 and streptomycin for 24 h. After being washed with PBS, the cells were placed in
32
33
34 fresh D-MEM and incubated further for 24, 48 and 72 h. Cell viability was measured
35
36
37 using a CellTiter-Glo® Luminescent Cell Viability Assay kit with microplate
38
39
40
41 luminometer device [MicroLumat Plus LB 96V, Berthold technologies, (Bad Wildbad,
42
43
44 Germany]].
45
46
47
48
49
50

51 *2.5. Expression and purification of recombinant forms of EGFP and EGFP-11R*

52
53
54 The recombinant forms of enhanced green fluorescent protein (EGFP) and eleven
55
56
57 poly-arginine-fused EGFP (EGFP-11R) were produced as described previously [17].
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 *2.6. Confocal laser microscopic analysis*
8

9
10 Cells (2×10^5) were plated onto 35-mm-diameter glass-bottomed dishes (Iwaki,
11 Tokyo, Japan) coated with laminin and cultured for 48 h. Cells were preincubated with
12 50 μ m PB or PBS for 2 min at 37 °C. 20 min after the transduction of 5 μ M EGFP and
13 EGFP-11R, the cells were washed twice with PBS and the medium was replaced with
14 D-MEM containing 10% (v/v) calf serum, 1% penicillin and streptomycin. The EGFP
15 signals in living cells were observed using a confocal laser microscope (FV300,
16 Olympus, Tokyo, Japan) equipped with a 60 x objective lens at 0.5, 2, 4 and 8 h after
17 protein transduction.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34
35
36
37
38 *2.7. Western blotting analysis*
39
40

41 Western blotting was carried out at high stringency, essentially as described
42 previously [18]. The harvested cells were lysed by a sonicator in a boiled buffer
43 containing 1% SDS. The cell lysate (50 μ g) was subjected to SDS-PAGE and
44 transferred to nitrocellulose membranes (Hybond ECL, Amersham Biosciences). The
45 blots were probed with primary antibodies against tyrosinase (1:100) (Abcam, Tokyo,
46 Japan). Immunoreactive bands were visualized by enhanced chemiluminescence using
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 ECL plus (GE Healthcare UK Ltd, Buckinghamshire, England) and Bio-Rad Versadoc
4
5
6 (Model 5000, Bio-Rad Laboratories, Inc., Hercules, CA).
7
8
9

10 11 12 13 *2.8. Measurement of melanin contents*

14
15
16 Melanin content was measured described previously [19]. Briefly, B16-4A5 cells
17
18 dissolved in 1ml of 5% Trichloroacetic acid (TCA) were incubated on ice for 10 min.
19
20
21 After centrifugation, the precipitate was dissolved in 2ml of EtOH-ether (3:1) and
22
23
24 centrifuged. The precipitate was resuspended in 2ml of ether, and centrifuged for 10
25
26
27 min. Finally, the precipitate was air-dried, and resuspended in 0.5 ml of 2 N NaOH at
28
29
30 80 °C for 1 hr. The absorbance at 415 nm was measured.
31
32
33
34
35
36
37

38 *2.9. Topical application of EGFP-11R and EGFP*

39
40
41 The hair from the back of adult guinea pigs (Female Weiser-Maples, SHIMIZU
42
43
44 Laboratory Supplies, Kyoto, Japan) weighing 450–500 g was removed carefully using
45
46
47 depilatory cream 24 h before the study. All procedures of animal experiments were
48
49
50 approved by the Animal Ethics Committee of Okayama University (OKU-2008019).
51
52
53 Areas of 4.0 cm² were marked on the dorsal trunk of the animals using a template. For
54
55
56
57 topical treatment of EGFP-11R, PB in propylene glycol [a mixture of 1 μL of PB (50
58
59
60
61
62
63
64
65

1
2
3 mM) and 99 μ L of propylene glycol] was pre-applied on the skin. After 5 min,
4
5
6 11R-EGFP [a mixture of 25 μ l of 11R-EGFP (50 μ M) and 25 μ l of propylene glycol]
7
8
9 was applied to the same region. As a control, EGFP or EGFP-11R [a mixture of 25 μ l
10
11
12 of 11R-EGFP or EGFP (50 μ M each) and 25 μ l of propylene glycol] was applied on the
13
14
15 skin of same guinea pigs. Skin sections were obtained at 0.5, 2, 4, and 8 h after the
16
17
18 topical applications with a 3-mm dermapunch (Maruho, Osaka, Japan). Excised skin
19
20
21 samples were immediately frozen in Optimal Cutting Temperature compound (Sakura
22
23
24 Finetek, Japan) and sequentially sectioned at a thickness of 10 μ m. The sections were
25
26
27 fixed with 4% PFA in 0.1 M phosphate buffer (pH 7.4) for 15 min. After being
28
29
30 washed with PBS, the sections were incubated with Hoechst 33258 (1 μ g/ml) for 5 min,
31
32
33 and viewed using a confocal microscope (FluoView™ FV300, Olympus, Tokyo, Japan).
34
35
36
37
38
39
40

41 2.10. *UV-induced pigmentation and topical treatment in vivo*

42
43
44 Hyperpigmentation was induced on the backs of brown guinea pigs by the modification
45
46
47 of a method as described previously [20]. Four separate areas (2 cm x 3 cm square)
48
49
50 on the back were shaved and exposed to UV from Model UVM-57 lamps (Funakoshi,
51
52
53 Tokyo, Japan), The total dose of UV was 15 mJ/cm² per day. Animals were exposed
54
55
56 five days a week for two consecutive weeks (Fig. 2). Two days after the last UV
57
58
59
60
61
62
63
64
65

1
2
3 irradiation, HQ (a mixture of 50 μ l of 1 mM HQ and 50 μ l of propylene glycol) was
4
5
6 applied to the tanning lesion. HQ-11R and HQ-GLHFPHIYVRD (a mixture of 50 μ l
7
8
9 of 1mM HQ or HQ-peptide and 50 μ L of propylene glycol) were applied to the tanning
10
11
12 lesion 5 min after pre-treatment with PB (a mixture of 1 μ l of 50 mM PB and 99 μ l of
13
14
15 propylene glycol) . Guinea pigs were treated with HQ and HQ-peptides once a day, 5
16
17
18 days a week, for a total of 10 days (Fig. 2). Three days after the last treatment, the
19
20
21 animals were sacrificed and skin samples were taken with a 3-mm dermapunch (Maruho,
22
23
24 Japan). As a control, the guinea pigs were received 100 μ l of propylene glycol.
25
26
27
28
29
30

31 2.11. *Histology study*

32
33
34 Under general euthanasia, skin was removed and fixed in 4% paraformaldehyde in PBS.
35
36
37 After paraffin processing, paraffin, embedded tissue sections 4.5 μ m thick were
38
39
40 processed for light microscopic examination. A hematoxylin and eosin (H&E) stain
41
42
43 was used for studying the general histopathological changes in the skin. Melanin
44
45
46 pigments were visualized with Fontana-Masson sliver staining followed by eosin
47
48
49 background staining as described previously [21]. Melanin-positive cells were
50
51
52 counted in a 500 x 400 μ m area in 20 different fields.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2.12. *Statistical analysis*

Data are shown as the mean \pm S.D. Data were analyzed using either Student's t-test to compare two conditions or ANOVA followed by planned comparisons of multiple conditions, and $P < 0.05$ was considered to be significant.

1
2
3 **3. Results**
4
5

6 ***3.1 Effect of poly-arginine-fused HQ (HQ-11R) with 1-pyrenebutyric acid (PB) on the***
7 ***viability of B16-4A5 melanoma cells.***
8
9

10
11
12 To investigate the cell toxicity of HQ-11R with PB in B16-4A5, a cell line of mouse
13 melanoma, the cells were incubated with each concentration of HQ and HQ-11R.
14
15
16 When the cells were incubated with 0.5 and 5.0 μM of HQ alone or of HQ-11R with 50
17
18
19 μM PB, viability was the same as that of the control after 24, 48 and 72 h (Fig. 3A),
20
21
22 suggesting that neither HQ and nor HQ-11R with PB had cell toxicity when used at
23
24
25 concentrations of 0.5 and 5 μM . Viability was significantly inhibited when the cells
26
27
28 were treated with 50 μM of HQ-11R. However, 50 μM of HQ also inhibited cell
29
30
31 viability the same as HQ-11R (Fig. 3A), suggesting the inhibitory effect to be due to
32
33
34 HQ.
35
36
37
38
39
40
41
42
43

44 ***3.2 Inhibitory effect of HQ-11R on melanin content.***
45
46

47
48 To investigate whether HQ-11R inhibited melanogenesis, B16-4A5 cells were
49
50
51 incubated with 10, 20 and 30 μM of HQ and HQ-11R and melanin content was
52
53
54 measured. Both HQ and HQ-11R dose-dependently inhibited melanin synthesis (Fig.
55
56
57 3B). The inhibitory effect of HQ-11R was the same as that of HQ (Fig. 3B). HQ
58
59
60
61
62
63
64
65

1
2
3 fused with a control peptide (HQ-GLHFPHIVRD), which consisted of eleven amino
4
5
6 acids and had no ability to penetrate cells, did not inhibit melanin synthesis when used
7
8
9 at 10 and 20 μ M (Fig. 3B). HQ –GLHFPHIVRD inhibited melanin synthesis at 30 μ M
10
11
12 but its effect was weaker than HQ-11R and HQ alone (Fig. 3B). The 11R-peptide
13
14
15 without HQ had no effect on melanin synthesis (Fig. 3B). HQ is a potent inhibitor of
16
17
18 tyrosinase, a key enzyme in melanin synthesis, but did not affect the expression or
19
20
21 degradation of the enzyme [22,23]. Some tyrosinase inhibitors display a
22
23
24 hypopigmenting effect through post-transcriptional control of the tyrosinase. Linoleic
25
26
27 acid decreases the amount of tyrosinase through increased tyrosinase ubiquitination and
28
29
30 degradation by the proteasome [23]. *N*-Acetylglucosamine reduced melanin synthesis
31
32
33 through the inhibition of tyrosinase glycosylation [24]. To investigate the possibility
34
35
36 that the inhibitory effect of HQ-11R on melanin synthesis was due to the
37
38
39 post-transcriptional control of tyrosinase, tyrosinase levels were examined in B16-4A5
40
41
42 cells treated with HQ and HQ-11R. Neither HQ nor HQ-11R affected the protein level
43
44
45 (Fig. 3C), suggesting that HQ-11R may inhibit melanin synthesis through the inhibition
46
47
48 of tyrosinase activity.
49
50
51
52
53
54
55
56

57 ***3.3 Transdermal delivery of EGFP-11R with PB.***

58
59
60
61
62
63
64
65

1
2
3 Next, the efficiency of the delivery of EGFP fused with 11R (EGFP-11R) in
4
5
6 B16-4A5 cells was examined. EGFP without 11R was not observed in the cells (Fig.
7
8
9 4A). The signals were observed in almost all of the cells 30 min after the addition of
10
11
12 EGFP-11R regardless of PB (Fig. 4A). Strong signals were observed 2, 4 and 8 h after
13
14
15 the transduction regardless of PB (Fig. 4A). Preincubation of PB did not affect the
16
17
18 efficiency of EGFP-11R transduction in the cells (Fig. 4A).
19
20
21

22 We next examined the effectiveness of the topical application of EGFP-11R. When
23
24
25 EGFP was topically applied, the signals were only observed on the surface of the skin
26
27
28 (Fig. 4B). The topical application of EGFP-11R without PB delivered the protein into
29
30
31 the dermis (Fig. 4B). However, signals were not observed in the epidermal layer (Fig.
32
33
34 4B). Strong signals in the epidermal layer were observed 0.5 and 2 h after the
35
36
37 application but the signals were faint at 4 and 8 h. When EGFP-11R was applied with
38
39
40 PB, strong signals were detected in both epidermis and dermis 0.5 and 2 h after the
41
42
43 application (Fig. 4B). Moreover, the signals were spread out more and stronger in
44
45
46 both layers after 4 and 8 h (Fig. 4B).
47
48
49

50
51 To investigate whether EGFP-11R was delivered in the cells of the epidermis and
52
53
54 dermis, the skin sections were counter-stained with Hoechst (Fig. 4C). Most EGFP
55
56
57 signals did not overlap with Hoechst staining when EGFP-11R was applied without PB,
58
59
60
61
62
63
64
65

1
2
3 suggesting that 11R-EGFP was delivered in the space of the epidermal layer (Fig. 4C).

4
5
6 In contrast, when EGFP-11R was applied with PB, the signals overlapped with Hoechst
7
8
9 staining in the cells of both epidermis and dermis 4 h after the application (Fig. 4C).

10 11 12 13 14 15 16 ***3.4 Inhibitory effect of HQ-11R on UV-induced pigmentation in guinea pig skin.***

17
18
19 The whitening effect of HQ-11R was examined using UV-induced pigmentation of
20
21
22 brown guinea pig skin. After UV irradiation for 10 days, guinea pigs were topically
23
24
25 treated with HQ, and HQ-11R and HQ-GLHFPHIYVRD with PB for 10 days (Figs 2 &
26
27
28 5A). The treatments did not induce abnormal morphological changes in the epidermis
29
30
31 and dermis (Fig. 5B). The HQ application tended to decrease levels of melanin but not
32
33
34 significant (Fig. 5B & C). HQ-11R significantly reduced melanin levels in the basal
35
36
37 cell layer of the epidermis whereas HQ-GLHFPHIYVRD lacking the ability to
38
39
40 penetrate cells had no effect on melanin levels in the epidermis (Fig. 5C).

4. Discussion

Protein transduction method using CPPs such as 11R is widely accepted as useful for the delivery of proteins, peptides and cell-impermeable molecules into cells [25]. Previous studies have showed the effective transdermal skin delivery of proteins and peptides employing CPPs including Tat (Trans-activating transcriptional activator), YARA, WLR, and 9R peptides [26-29]. In the present study, we also showed that protein transduction method using 11R was valuable for the transdermal delivery of EGFP and HQ. However, EGFP-11R without PB was not delivered into cells of the epidermis although signals were observed in the layer. These results suggest that protein transduction using CPPs is capable of increasing the penetration of skin by proteins but most proteins delivered topically do not enter or function in cells of the epidermis and dermis. In contrast, EGFP-11R was delivered to cells of the epidermis and dermis and HQ-11R reduced melanin levels in the basal cell layer of epidermis when applied in combination with 4-(1-pyrenyl)-butyric acid (PB), suggesting that PB enhances the intracellular delivery of proteins and hydrophilic molecules delivered transdermally. The molecular mechanism by which CPP-fused proteins cross the cell membrane is different with that without PB. CPP fusion proteins are internalized rapidly by lipid raft-dependent macropinocytosis [11]. In contrast, the negatively

1
2
3 charged counteranions and high hydrophobicity of PB can exert a great influence on the
4
5
6 translocation behavior of arginine peptides in artificial membranes [12,13].
7

8
9 Endogenous mechanism such as macropinocytosis and endocytosis are not necessary
10
11 for the intracellular delivery of poly-arginine fusion proteins when applied with PB.
12
13

14
15 The artificial membrane penetration may be convenient for the transdermal delivery of
16
17 poly-arginine fusion proteins.
18
19

20
21
22 The backbone of PB is a pyrene, a polycyclic aromatic hydrocarbon consisting of
23
24 four fused benzene rings and it contains a hydrophilic carboxylic acid. The structure is
25
26 similar with benzopyrene, which consists of five benzene rings. Benzopyrene is found
27
28 in coal tar and cigarette smoke, and shows an evidence of carcinogenicity in lung cells
29
30 [30]. Therefore, PB is misunderstood to have toxicity. However, a previous study
31
32 showed that PB had no significant cytotoxicity [12]. In the present study, moreover,
33
34 PB did not affect the growth of B16-4A5 nor cause dermatitis in guinea pigs. These
35
36 results suggest protein transduction using 11R and PB to be safe as a transdermal
37
38 delivery method. However, further study is needed.
39
40
41
42
43
44
45
46
47
48
49

50
51 A previous study showed that bioactive proteins were transdermally delivered by
52
53 non-covalently associated poly-arginine peptides [27]. We also examined whether HQ
54
55 non-covalently associated with 11R was delivered in the dermis and epidermis of guinea
56
57
58
59
60
61
62
63
64
65

1
2
3 pigs when applied with 11R. However, HQ was not delivered in the skin (data not
4
5
6 shown). These results suggest that transdermal delivery by non-covalently associated
7
8
9 poly-arginine peptides may be suitable for proteins and peptides but not low molecules.
10

11
12 In conclusion, a topical approach using poly-arginine in combination with PB was
13
14 proven to be beneficial for the delivery of proteins and hydrophilic drugs. HQ-11R is a
15
16 candidate for a skin-whitening agent with the advantages of strong tyrosinase inhibition,
17
18
19 effective penetration of the skin, and relatively little cytotoxicity.
20
21
22
23
24
25
26
27

28 **4. Conclusion**

29
30 The present results showed that a poly-arginine (11R) with pre-treatment of PB
31
32 was effective at topical delivering system to enter or function in cells of the epidermis
33
34 and dermis. It appears that our system can be used to deliver many kinds of proteins
35
36 and whitening-agents into g transcription factors into various cells. *In vivo* topical
37
38 protein transduction method with pyrenbutyrate may overcome the disadvantages of
39
40 previous methods and become a promising modality in dermatological field and
41
42 cosmetics industry.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgements

We thank A. Ueda for technical assistance. This work was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan and by a Grant-in-aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan.

Fig. 1




Fig. 2






Fig. 3

A



B



C






Fig. 4

A



B



C






Fig. 5

A



B



C




Figure legends

Fig. 1. The schema of HQ-11R synthesis.

Fig. 2. Time schedule of UV-irradiation and applications of HQ and HQ-11R.

Fig. 3. Comparison of the inhibitory effect on melanin synthesis between hydroquinone (HQ) and eleven poly-arginine-fused HQ (HQ-11R) in B16-4A5 melanoma cells. (A) Cell viability was measured by the *Cell Titer-Glo Luminescent Cell Viability* assay. B16-4A5 cells were treated with 10, 20 and 30 μM of HQ alone or HQ-11R in the presence of PB for the periods indicated. Control cells (Cont.) were intact cells. Data are represented as the mean \pm SD. $n=6$ each. (B) Measurement of melanin contents in the cells treated with 10, 20 and 30 μM of HQ, HQ-11R, HQ-GLHFPHIYBRD and 11R peptide for 24 h. Data are represented as the mean \pm SD. $n=6$ each. $*P < 0.05$, $**P < 0.01$ (C) Effect of HQ and HQ-11R on tyrosinase levels in B16-4A5 cells. The cells were treated with HQ alone and HQ-11R with PB for the periods indicated. The cells were harvested at each time point and the lysates were used for Western blotting.

Fig. 4. Transdermal transduction of EGFR-11R with PB. (A) Time-dependent transduction of EGFR-11R with or without PB in B16-4A5 cells. The cells were treated with 1 μ M EGFP-11R (EGFP-11R). After pre-treatment with PB for 5 min, 1 μ M EGFP was added (EGFP-11R + PB). The signals were observed by confocal microscopy at each time point. Bars = 10 μ m. (B) Time-dependent transdermal delivery of EGFP-11R. EGFP and EGFP-11R with/without PB were applied on the skin of guinea pigs. Skin sections were obtained at each time point and EGFP signals were observed with a confocal microscope. Bars = 200 μ m. (C) The distribution of EGFP-11R in the epidermis and dermis of guinea pigs. EGFP-11R was applied with or without PB. The skin sections were counter-stained with Hoechst 33258 (blue). Bars = 50 μ m.

Fig. 5. Inhibitory effect of HQ-11R on UV-induced pigmentation in guinea pig skin. (A) A representative image of the back of the Guinea pigs pre-radiation, post-radiation, and pre-treatment and post-treatment with HQ, HQ-non CPP peptide and HQ-11R. Each area is 2cm x 2cm square. (B) Biopsy specimens from HQ-, HQ-11R- or HQ-GLHFPHIYVRD-treated guinea pig skin after 10 days of topical application were examined by H.E. staining (upper panel) and Fontana-Masson silver

staining (lower panel). Bars = 50 μm . (C) Number of cells positive for Fontana-Masson stain. The positive cells were counted in a 500 x 400 μm area in 20 different fields. *P < 0.01.

AUTHOR DECLARATION

We the undersigned declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. We would like to draw the attention of the Editor to the following publications of one or more of us that refer to aspects of the manuscript presently being submitted. Where relevant copies of such publications are attached. We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work. [OR] We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from biomaterials@online.be.

Signed by all authors as follows:

CANDANGERILE	<u>CANDANGERILE II</u>	date: <u>11/4/2012</u>
Hiroyuki Michine	<u>Hiroyuki Michine</u>	date: <u>4/10/2012</u>
Sanue Ishikawa	<u>Sanue Ishikawa</u>	date: <u>4/11/2012</u>
Atsushi Fujimura	<u>Atsushi Fujimura</u>	date: <u>4/11/2012</u>
Keiichiro Hayashi	<u>Keiichiro Hayashi</u>	date: <u>4/11/2012</u>
Atsuhito Ueda	<u>Atsuhito Ueda</u>	date: <u>4/11/2012</u>
Akiko Mori	<u>Akiko Mori</u>	date: <u>4/11/2012</u>
Iori Ohmori	<u>Iori Ohmori</u>	date: <u>4/11/2012</u>
Tei-ichi Nishiki	<u>Tei-ichi Nishiki</u>	date: <u>4/11/2012</u>
Hideki Matsui	<u>Hideki Matsui</u>	date: <u>4/11/2012</u>
Kazuhito Tomizawa	<u>Kazuhito Tomizawa</u>	date: <u>4/11/2012</u>

1
2
3 **References**
4

- 5 [1] Liu CH, Chang FY, Development and characterization of eucalyptol
6 microemulsions for topic delivery of curcumin, Chem Pharm Bull
7 2011;59:172-178.
8
9
10
11 [2] Kogan A, Garti N, Microemulsions as transdermal drug delivery vehicles. Adv
12 Colloid Interface Sci 2006;123-126:369-385.
13
14
15
16 [3] Matsui H, Tomizawa K, Lu YF, Matsushita M, Protein Therapy: In vivo protein
17 transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr
18 Protein Pept Sci 2003;4:151-157.
19
20
21
22 [4] Tomoda K, Terashima H, Suzuki K, Inagi T, Terada H, Makino K, Enhanced
23 transdermal delivery of indomethacin-loaded PLGA nanoparticles by
24 iontophoresis. Colloids Surf B Biointerfaces 2011;88:706-710.
25
26
27
28 [5] Shah VP, Behl CR, Flynn GL, Higuchi WI, Schaefer H, Principles and criteria
29 in the development and optimization of topical therapeutic products. J Pharm Sci
30 1992;81:1051-1054.
31
32
33
34 [6] Nino M, Calabrò G, Santoianni P, Topical delivery of active principles: the field
35 of dermatological research. Dermatol Online J 2010;16:4.
36
37
38
39 [7] Korting HC, Stolz W, Schmid MH, Maierhofer G, Interaction of liposomes with
40 human epidermis reconstructed in vitro. Br J Dermatol 1995;132:571-579.
41
42
43
44 [8] Schwarze SR, Hrusk KA, Dowdy SF, Protein transduction: unrestricted delivery
45 into all cells? Trends Cell Biol 2000;10:290-295.
46
47
48
49 [9] Futaki S (Ed.), Special theme issue on membrane permeable peptide vectors:
50 chemistry and functional design for the therapeutic application, Adv Drug Delivery
51 Rev 2008;60:447-614.
52
53
54
55 [10] Joliot A, Prochiantz A, Transduction peptides: from technology to physiology, Nat
56 Cell Biol 2004;6:189-196.
57
58
59
60
61
62
63
64
65

- 1
2
3
4 [11] Wadia JS, Stan RV, Dowdy SF, Transducible TAT-HA fusogenic peptide
5 enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. *Nat*
6 *Med* 2004;10:310-315.
7
8
9
10 [12] Takeuchi T, Kosuge M, Tadokoro A, Sugiura Y, Nishi M, Kawata M, Direct and
11 rapid cytosolic delivery using cell-penetrating peptides mediated by
12 pyrenebutyrate. *ACS Chem Biol* 2006;1:299-303.
13
14
15 [13] Guterstam P, Madani F, Hirose H, Takeuchi T, Futaki S, El Andaloussi S,
16 Elucidating cell-penetrating peptide mechanisms of action for membrane
17 interaction, cellular uptake, and translocation utilizing the hydrophobic
18 counter-anion pyrenebutyrate. *Biochim Biophys Acta*. 2009;1788:2509-2517.
19
20
21 [14] Westerhof W, Kooyers TJ, Hydroquinone and its analogues in dermatology-a
22 potential health risk. *J Cos Dermatol* 2005;4:55-59.
23
24
25 [15] Nordlund JJ, Grimes PE, Ortonnes JP, The safety of hydroquinone, *J Eur Acad*
26 *Dermatol Venereol* 2006;20:781-787.
27
28
29 [16] Chen YR, Y-Y R, Lin TY, Huang CP, Tang WC, Chen ST, Identification of an
30 alkylhydroquinone from *Rhus succedanea* as an inhibitor of tyrosinase and
31 melanogenesis, *J Agric Food Chem* 2009;57: 2200-2205.
32
33
34 [17] Matsushita M, Tomizawa K, Moriwaki A, Li ST, Terada H, Matsui H, A
35 high-efficiency protein transduction system demonstrating the role of PKA in
36 long-lasting long-term potentiation, *J Neurosci* 2001;21:6000-6007.
37
38
39 [18] Takenobu T, Tomizawa K, Matsushita M, Li ST, Moriwaki A, Lu YF,
40 Development of p53 protein transduction therapy using membrane-permeable
41 peptides and the application to oral cancer cells, *Mol Cancer Ther*
42 2002;1:1043-1049.
43
44
45 [19] Fujita H, Motokawa T, Katagiri T, Yokota S, Yamamoto A, Himeno M,
46 Inulavosin, a melanogenesis inhibitor, leads to mistargeting of tyrosinase to
47 lysosomes and accelerates its degradation, *J Invest Dermatol*
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 2009;129:1489-1499.
3
4

- 5 [20] Kim JH, Baek SH, Kim DH, Choi TY, Yoon TJ, Hwang JS, Downregulation of
6 melanin synthesis by haginin A and its application to in vivo lightening model, J
7 Invest Dermatol 2008;128:1227-1235.
8
9
10
11 [21] Park KT, Ki JK, Hwang D, Yoo Y, Lim YH, Inhibitory effect of mulberroside A
12 and its derivatives on melanogenesis induced by ultraviolet B irradiation, Food
13 Chem Toxicol 2011;49:3038-3045.
14
15
16
17 [22] Maeda K, Fukuda M, Arbutin: mechanism of its depigmenting action in human
18 melanocyte culture, J Pharmacol Exp Ther 1996;276:765-769.
19
20
21
22 [23] Kim H, Choi HR, Kim DS, Park KC, Topical hypopigmenting agents for
23 pigmentary disorders and their mechanisms of action, Ann Dermatol 2012;24:1-6.
24
25
26
27 [24] Hwang JS, Lee HY, Lim TY, Kim MY, Yoon TJ, Disruption of tyrosinase
28 glycosylation by N-acetylglucosamine and its depigmenting effects in guinea pig
29 skin and in human skin, J Dermatol Sci 2011;63:199-201.
30
31
32
33 [25] van den Berg A, Dowdy SF, Protein transduction domain delivery of therapeutic
34 macromolecules, Curr Opin Biotechnol 2011;22:888-893.
35
36
37
38 [26] Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, Mcgrane PL,
39 Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and
40 inhibition of inflammation, Nat Med 2000;6:1253-1257.
41
42
43
44 [27] Hou YW, Chan MH, Hsu HR, Liu BR, Chen CP, Chen HH, Transdermal delivery
45 of proteins mediated by non-covalently associated arginine-rich intracellular
46 delivery peptides, Exp Dermatol 2007;16:999-1006.
47
48
49
50 [28] Lopes LB, Furnish E, Komalavilas P, Seal BL, Panitch A, Bentley MV, Enhanced
51 skin penetration of P20 phosphopeptide using protein transduction domains, Eur J
52 Pharm Biopharm 2008;68:441-445.
53
54
55
56 [29] Kang MJ, Eum JY, Park SH, Kang MH, Park KH, Choi SE, Pep-1
57
58
59
60
61
62
63
64
65

1
2 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the
3 treatment of atopic dermatitis in NC/Nga mice, Int J Pharm 2010;402:198-204.
4
5

- 6
7 [30] Denissenko MF, Pao A, Tang M, Pfeifer GP, Preferential formation of
8 benzo[a]pyrene adducts at lung cancer mutational hotspots in P53, Science
9 1996;274:430-432.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

**Combining Poly-Arginine with the Hydrophobic Counter-anion
4-(1-Pyrenyl)-Butyric Acid for Protein Transduction in Transdermal Delivery**

**CANDANGERILE^{1*}, Hiroyuki Michiue^{1*#}, Sanae Ishikawa¹, Atsushi Fujimura¹,
Keiichiro Hayashi¹, Atsuhito Uneda¹, Akiko Mori¹, Iori Ohmori¹, Tei-ichi Nishiki¹,
Hideki Matsui¹, and Kazuhito Tomizawa²**

1. Departments of Physiology Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-Ku, Okayama
700-8558 Japan.

2. Department of Molecular Physiology, Faculty of Life Sciences, Kumamoto
University, 1-1-1 Honjou, Kumamoto, 860-8556 Japan

Running title: 11R-peptide transdermal approach

Key words: Transdermal delivery, Protein transduction, Poly-arginine, 11R, Tat,
Hydroquinone, Melanin, Skin, Tyrosinase inhibitor

* These authors contributed equally to this work.

Address Correspondence to:

Dr. Hiroyuki Michiue

Department of Physiology

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences,

Shikata-cho 2-5-1, Okayama 700-8558, Japan,

Tel.: +81-86-235-7105

Fax: +81-86-235-7111,

E-mail: hmichiue@md.okayama-u.ac.jp

Okayama University Graduate
2-5-1 Shikata-cho,



School of Medicine & Dentistry
Okayama 700-8558, Japan

Prof. D.F. Williams,
Editor-in-Chief
Biomaterials

April, 23, 2012

Dear Prof. Williams:

Thank you for reviewing our paper and providing an opportunity for revision. We have carefully read the comments by the Editor and the reviewer, and changed the manuscript accordingly.

We hope that this revised version is considered worthy of publication in **Biomaterials**. We appreciate your thoughtful review of this work, and look forward to hearing from you soon.

Answers to mandatory editor's requirements

1. We changed the title to " Combining Poly-Arginine with the Hydrophobic Counter-anion 4-(1-Pyrenyl)-Butyric Acid for Protein Transduction in Transdermal Delivery ".

Sincerely yours,

Hiroyuki Michiue M.D. Ph.D

Assistant Professor

Department of Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1, Okayama 700-8558, JAPAN

Tel: 81-86-235-7105, Fax: 81-86-235-7111

E-mail: hmichiue@md.okayama-u.ac.jp